- 1 Supplementary information
- 2 **Supplementary Figure S1.** Participant flow diagram. The cohorts were primed with the primary
- 3 series of CV and received a reduced dose (experimental group) or standard dose (comparative
- 4 group) of the mRNA vaccine.


5

6

7


8

Two doses of CoronaVac-immunized heathy adults




Y Previously enrolled by Assawakosri et al., 2022

Supplementary Figure S2. Reactogenicity after receiving mRNA vaccine for 7 days post-vaccination. The participants received two completed doses of the inactivated vaccine, CoronaVac, followed by A) 15 μg-BNT162b2, B) 30 μg-BNT162b2, C) 50 μg-mRNA-1273, or D) 100 μg-mRNA-1273. Participant percentages are shown on the Y-axis. Swelling and redness were graded by measuring the diameter area as mild (<5 cm), moderate (5 to <10 cm), and severe (≥10 cm). Fever was defined as mild (38.0-38.5 °C), moderate (38.5-39.0 °C), and severe (39.0 °C). Local and systemic symptoms were graded as mild (easily tolerated with no limitation on regular activity), moderate (some limitation of daily activity), and severe (unable to perform the regular daily activity).



Supplementary Figure S3. IgG anti nucleoprotein (N) of SARS-CoV-2 index (S/C). Serum samples were obtained from participants who received two completed doses of the inactivated vaccine, CoronaVac, followed by 15 μ g (reduced) mRNA vaccine–BNT162b2, 30 μ g (standard) mRNA vaccine–BNT162b2, 50 μ g (reduced) mRNA-1273, or 100 μ g (standard) mRNA-1273. Lines represent the median (interquartile range).





	BNT162b2 (15 μg)	BNT162b2 (30 μg) ^γ	mRNA-1273 (50 μg)	mRNA-1273 (100 μg) ^γ
Humoral responses				
Ig anti-RBD (U/mL)				
V1 (Baseline), n	59	54	51	58
GMT (95% CI)	45.01 (32.86-61.65)	41.67 (31.38-55.32)	41.06 (29.05-58.03)	27.07 (20.44-35.84)
V2 (Second visit), n	56	54	51	57
GMT (95% CI)	28413 (24781-32578)	31793 (27428-36852)	41171 (34563-49043)	51979 (43920- 61516)
V3 (Third visit), n	56	54	49	56
GMT (95% CI)	21299 (18390-24667)	21053 (18145-24428	27282 (23082-32245)	33519 (28228- 39802)
IgG anti-RBD (BAU/mL)	1			
V1 (Baseline), n	59	54	51	58
GMT (95% CI)	22.91 (17.88-29.37)	26.01 (21.16-31.97)	22.52 (17.70-28.64)	18.13 (14.78-22.23)
V2 (Second visit), n	56	54	51	57
GMT (95% CI)	4609 (4009-5299)	4878 (4222-5636)	7476 (6167-9062)	8901 (7471-10605)
V3 (Third visit), n	56	54	49	56
GMT (95% CI)	3994 (3455-4618)	3837 (3292-4472)	5416 (4523-6485)	6570 (5694-7580)
IgG anti-N (S/C)				
V1 (Baseline), n	59	54	51	58
Median (IQR)	0.09 (0.07-0.19)	0.15 (0.10-0.36)	0.15 (0.09-0.23)	0.13 (0.07-0.33)
V2 (Second visit), n	56	54	51	57
Median (IQR)	0.15 (0.08-0.29)	0.14 (0.09-0.41)	0.17 (0.09-0.25)	0.14 (0.09-0.37)
V3 (Third visit), n	56	54	49	56
Median (IQR)	0.15 (0.07-0.27)	0.12 (0.08-0.31)	0.15 (0.07-0.22)	0.12 (0.07-0.31)
Neutralization assays: VN	NT-Delta (%inhibition)			
V3 (Third visit), n	29	30	30	30
Median (IQR)	97.4 (97.2-97.5)	97.5 (97.3-97.6)	97.4 (97.2-97.4)	98.2 (98.2-98.3)
Neutralization assays: VN	NT-Omicron (%inhibition)			
V3 (Third visit), n	29	30	30	30
Median (IQR)	71.2 (43.7-84.2)	53.5 (26.3-70.0)	61.1 (44.5-81.5)	76.7 (60.6-91.6)
Neutralization assay: FR	NT-Delta (dilution)			
V3 (Third visit), n	30	30	30	30
GMT (95% CI)	1505 (1126- 2012)	1285 (982.2-1680)	2088 (1441-3025)	2168 (1627-2889)
Neutralization assay: FR	NT-Omicron (dilution)			
V3 (Third visit), n	30	30	30	30
GMT (95% CI)	343.4 (244.6- 482.1)	276.6 (190.1-402.3)	521.1 (352.4-770.7)	512.5 (358.7-732.2)

T-cell responses				
IFN-γ CD4 ⁺ (IU/mL)				
V1 (Baseline), n	30	27	29	31
Median (IQR)	0.01 (-0.02-0.103)	0.05 (0.01-0.19)	0.03 (0.01-0.08)	0.03 (-0.01-0.20)
V2 (Second visit), n	30	27	28	31
Median (IQR)	0.72 (0.18 - 1.72)	1.12 (0.41-2.22)	1.18 (0.19-2.39)	0.90 (0.25-1.78)
V3 (Third visit), n	30	27	29	31
Median (IQR)	0.30 (0.15-1.22)	0.74 (0.20-1.46)	0.66 (0.15-1.46)	0.77 (0.26-1.83)
IFN-γ CD4 ⁺ CD8 ⁺ (IU/mL)				
V1 (Baseline), n	30	27	29	31
Median (IQR)	0.02 (-0.02-0.20)	0.10 (0.02-0.23)	0.03 (-0.01-0.13)	0.11 (0.00-0.31)
V2 (Second visit), n	30	27	28	31
Median (IQR)	1.00 (0.34-3.19)	2.22 (0.82-2.70)	1.59 (0.24-3.11)	1.68 (0.39-2.68)
V3 (Third visit), n	30	27	29	31
Median (IQR)	0.44 (0.14-2.11)	1.02 (0.29-2.40)	0.93 (0.35-1.88)	1.03 (0.40-2.31)

⁴⁰ μg indicates an amount of SARS-CoV-2 Spike protein encoded mRNA

⁴¹ Y the comparative group represents a regular dose of each mRNA COVID-19 vaccine as

previously reported by Assawakosri et al., 2011.